LBA1 | THE BENEFIT OF POLA‐R‐CHP IN DLBclass‐DEFINED MOLECULAR SUBSETS OF NEWLY DIAGNOSED DLBCL IN THE POLARIX TRIALEleonora Calabretta, Margaret A. Shipp, Maria C. Palazzo et al.|Hematological Oncology|2025Cited by 9
227 | RITUXIMAB AND EPCORITAMAB AS FIRST‐LINE THERAPY FOR PATIENTS WITH HIGH‐TUMOR BURDEN FOLLICULAR LYMPHOMA: FIRST RESULTS OF A MULTICENTER PHASE II TRIALR. Merryman, Yazeed Sawalha, D. S. Wallace et al.|Hematological Oncology|2025Cited by 1